CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We received an updated WNV package insert; please note the manufacturer and license number has been ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
We have now added a new section called the "Assay History List" to the "At A Gla...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...